Low dose of cyproterone acetate and testosterone enanthate for contraception in men

Human Reproduction
M Cristina MeriggiolaC Flamigni

Abstract

After a control phase, 10 normal men received cyproterone acetate (CPA) at a dose of 25 mg/day (CPA-25; n=5) or 12.5 mg/day (CPA-12.5; n=5) plus testosterone enanthate (TE) 100 mg/week, for 16 weeks. Throughout the study sperm counts were performed every 2 weeks, and luteinizing hormone (LH), follicle stimulating hormone (FSH), testosterone, biochemical and haematological tests were performed every 4 weeks. All five men in group CPA-25 and three men in group CPA-12.5 achieved azoospermia. One man in group CPA-25 was azoospermic by week 12 of hormone administration, but had a sperm count of 0.1 x 10(6)/ml at week 16. Time to azoospermia was 9.0+/-1.3 and 8.7+/-0.7 weeks in groups CPA-25 and CPA-12.5 respectively. Gonadotrophins were decreased by week 4 of hormone administration, remained around the minimum detectability of the assay for the duration of hormone administration and returned to baseline after stopping hormone administration. Testosterone values did not change. No change in any biochemical parameters was found. Haematological parameters were decreased at week 16 of hormone administration and returned to baseline after stopping hormone administration. In conclusion, these results suggest that an hormonal regimen consi...Continue Reading

Associated Clinical Trials

Citations

Apr 28, 2004·Molecular and Cellular Endocrinology·R John LyeAndrea Wagenfeld
Jan 16, 2004·Trends in Pharmacological Sciences·Axel Kamischke, Eberhard Nieschlag
May 22, 2002·Contraception·M C MeriggiolaS Cerpolini
Dec 12, 2003·Steroids·Eberhard NieschlagAxel Kamischke
Aug 29, 2003·The Journal of Steroid Biochemistry and Molecular Biology·John K Amory, William J Bremner
Feb 17, 2000·Trends in Endocrinology and Metabolism : TEM·J K Amory, W J Bremner
Mar 26, 2010·International Journal of Impotence Research·G J Manetti, S C Honig
Aug 26, 2006·Nature Clinical Practice. Endocrinology & Metabolism·John K AmoryWilliam J Bremner
Apr 26, 2008·Endocrine Reviews·Stephanie T PageWilliam J Bremner
Feb 12, 2009·Pakistan Journal of Biological Sciences : PJBS·E H A Ali
Mar 22, 2006·Expert Opinion on Investigational Drugs·Maria Cristina Meriggiola, Giuseppe Pelusi
Oct 5, 2001·Expert Opinion on Pharmacotherapy·B D Anawalt, J K Amory
Feb 28, 2002·Expert Opinion on Investigational Drugs·Brian M Brady, Richard A Anderson
Jul 21, 2006·The European Journal of Contraception & Reproductive Health Care : the Official Journal of the European Society of Contraception·Melanie Wenk, Eberhard Nieschlag
Aug 28, 2004·Expert Opinion on Investigational Drugs·Melanie Walton, Richard A Anderson
Jan 31, 2002·Annals of Medicine·B D Anawalt, J K Amory
Feb 25, 2000·Human Reproduction·D J HandelsmanA J Conway
Sep 17, 2018·Reviews in Endocrine & Metabolic Disorders·Natnita MattawanonVin Tangpricha
Dec 6, 2002·Endocrine Reviews·R A Anderson, D T Baird
Apr 7, 2006·Human Reproduction Update·Kati L Matthiesson, Robert I McLachlan
Feb 28, 2008·The Journal of Clinical Endocrinology and Metabolism·Peter Y LiuChristina Wang
Mar 16, 2012·The Cochrane Database of Systematic Reviews·David A GrimesKenneth F Schulz
Dec 13, 2003·The Journal of Clinical Endocrinology and Metabolism·M C MeriggiolaG Pelusi
Nov 7, 2003·The Journal of Clinical Endocrinology and Metabolism·Sigrid von EckardsteinUNKNOWN International Committee for Contraception Research, The Population Council
May 8, 2002·The Journal of Clinical Endocrinology and Metabolism·M Cristina MeriggiolaCarlo Flamigni
Dec 2, 2004·Expert Opinion on Emerging Drugs·Paul B Cornia, Bradley D Anawalt
Dec 2, 2005·Treatments in Endocrinology·John K Amory
May 28, 2019·Nature Reviews. Cardiology·Thiago Gagliano-Jucá, Shehzad Basaria
Jun 27, 2003·Journal of Andrology·M Cristina MeriggiolaMichael T Mbizvo
Apr 1, 2005·Treatments in Endocrinology·Nicole N Grant, Bradley D Anawalt
Feb 6, 2004·Acta Obstetricia Et Gynecologica Scandinavica·Antti Perheentupa, Ilpo Huhtaniemi

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.